This webinar will review additions and changes to monographs in the HPUS, including updates to quality control tests, revised attenuation levels, and modifications based on input originating outside the Convention. You will hear about new explanatory text regarding the Convention’s distinctions concerning marker compounds in relation to therapeutic activity.

The webinar will also provide you with information about an HPCUS project that is a priority in the coming months. This project will lead to documents focused on five cGMP related issues of particular importance for homeopathic drug products.

All manufacturers and marketers of homeopathic drug products need to be aware of this wide range of information to ensure your products and labeling do not fall into the FDA’s high-risk categories for enforcement action.

Attend this one-hour AAHP Compliance Thru Education webinar for an overview of these changes; attendees can receive (post-webinar) four documents listing the monographs affected by these updates.

Whether you manufacture or just market homeopathic drug products, the new information in the HPUS has a bearing on your products’ compliance status. Regulatory and FDA review of homeopathic products over the past year support the critical importance of being current with the updates in the HPUS. These changes and updates may affect your business, your cGMP compliance, your products, and your long-term success in the market!